WASHINGTON, June 13, 2017 /PRNewswire/ -- The Coalition
for Access to Prenatal Screening (CAPS) announced today that it has
assembled a clinical advisory board to advise the coalition on
medical and policy issues to help improve access to cell-free DNA
(cfDNA)-based noninvasive prenatal testing (NIPT) for all pregnant
women. Established in January 2017,
CAPS is comprised of: Illumina, Inc. (NASDAQ: ILMN); Counsyl, Inc.;
Progenity, Inc.; Natera, Inc. (NASDAQ: NTRA); and LabCorp® (NYSE:
LH) through its Integrated Genetics specialty laboratory.
Under the leadership of the clinical advisory board chairman
Arnold W. Cohen, MD, Chairman
Emeritus of the Department of Obstetrics and Gynecology at the
Einstein Healthcare Network, the CAPS Clinical Advisory Board also
includes:
- Anthony R. Gregg, MD,
MBA, FACOG, FACMG, B. L.
Stalnaker Professor Chief, Maternal Fetal Medicine,
Director, Obstetrics UF Health University of
Florida College of Medicine
- Aleksandar Rajkovic, MD,
PhD, Marcus Allen Hogge Chair in Reproductive Sciences,
Director of Medical Genetics, Medical Director of Pittsburgh
Clinical Genomics Laboratory, Magee
Women's Research Institute and Foundation, Department of
Obstetrics and Gynecology and Reproductive Sciences, University of Pittsburgh
- Annelise Skor Swigert, MD,
FACOG, Executive Partner at Southdale Obstetrics and
Gynecology; Chief Medical Officer, Premier ObGyn Minnesota
- Thomas Westover, MD,
FACOG, Vice Chair of the New Jersey Section of the American
College of Obstetrics and Gynecology; Co-Chair of the New Jersey
Hospital Association, Perinatal Safety Collaborative; Assistant
Professor, Maternal Fetal Medicine & ObGyn, Cooper Medical
School, Rowan University
- Jennifer Hoskovec, MS,
CGC, Director, Prenatal Genetic Counseling Services, Department
of Obstetrics, Gynecology and Reproductive Sciences, McGovern
Medical School, UTHealth
- Daniel S. Grosu, MD, MBA,
Founder of GENOPRAXIS, LLC and former Chief Medical Officer of
Sequenom and Illumina
The clinical advisory board members will provide CAPS with the
benefit of their respective clinical experience, access
to educational resources and assistance in the development of
evidence-based scientific studies in support of cfDNA
screening. Members of the clinical advisory board may
also represent CAPS at professional societies and
meetings.
"It's my pleasure to welcome my esteemed colleagues as advisors
to CAPS," said Cohen. "We look forward to working with the CAPS
member companies to provide reliable and useful information about
cfDNA-based NIPT to patients, healthcare providers, and public
and private insurers."
About CAPS
The Coalition for Access to Prenatal
Screening (CAPS) is a collaborative alliance of five leading
genetic testing companies in the United
States that seeks to improve access to state-of-the-art
prenatal screening using cell-free DNA (cfDNA)-based noninvasive
prenatal testing (NIPT) for all pregnant women who choose to pursue
aneuploidy screening – regardless of their risk factors, income,
age or geographic location. CAPS encourages appropriate
reimbursement coverage policy changes for this medically-actionable
testing service, which has the potential to improve personalized
patient care. For more information on CAPS, please click here.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/coalition-for-access-to-prenatal-screening-announces-clinical-advisory-board-300472771.html
SOURCE Coalition for Access to Prenatal Screening (CAPS)